• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Piramal acquires UK-based pharma firm

      Posted AtInternational Herald Tribune

      A day after announcing an agreement with AstraZeneca AB of Sweden for the manufacture of intermediate active ingredients and bulk drugs, Indian pharma giant, Nicholas Piramal India Ltd (NPIL), on Thursday announced the acquisition of Avecia Pharmaceuticals, part of the UK-based Avecia Group, for roughly Rs 77 crores, inclusive of Avecia's pension fund deficit between GBP 8-9 million.

      "India has the advantage of providing low-cost manufacturing facilities to the pharma industry. The pharma companies abroad offer access to high end technologies. Such acquisitions provide us access to these technologies and at the same time, help us establish a physical proximity to our clients. We would also be looking to expand our manufacturing capacity in India. Our organic growth comprise of contracts like the recent announcements with AstraZeneca, while acquisitions such as Avecia and Rhodia, represent the company's inorganic growth. Avecia also comprises of Torcan Chemical Ltd, in Canada and 25 per cent ownership in Reaxa Ltd," added Nicholas Piramal chairman, Mr Ajay Piramal.

      Commenting on the transaction, Mr Piramal said, "Avecia has a long tradition of technology-driven, high-end services for the global pharmaceutical industry, driven by highly competent specialists. The merger of this business with our custom manufacturing group will go a long way in making the combined entity a truly global custom manufacturing player. We are confident of this business growing in the coming years, based on our combined global business development strength, technological skills and inherent India advantage."

      This transaction is the first step in NPIL's strategy of establishing such a winning global footprint for its custom manufacturing business. The reconfigured asset base will include access to leading early phase assets, including nearly 100 early-phase and launched products.

      This acquisition is NPIL's second transaction in the UK, after that of Rhodia's Inhalation Anaesthetics business in December 2004. The transaction is in the nature of a share purchase on a liabilities and cash-free basis and includes a working capital of GBP 8.8 million.


      October 28, 2005

       

      Share this Article!

    Back to top^